“…2 Such a prodrug strategy has been used to create peptide–drug conjugates, 3 polymer–drug conjugates, 4 dendrimer–drug conjugates, 5 nanoparticle–drug conjugates, 6 and most recently drug-based molecular hydrogelators 7 and self-assembling drug amphiphiles. 8 Indeed, the linkage of a hydrophilic segment to a hydrophobic anticancer drug to create self-assembling amphiphiles offers the means to create self-delivering drugs that possess a high and fixed drug content, allowing for the minimum use of excipients. These self-assembling prodrugs combine the processability of small molecules with the controlled pharmacokinetics potential offered by larger structures such as polymer–drug conjugates.…”